
Releases
FDA Approves At-Home Subcutaneous Injection for Early Alzheimer's
The U.S. Food and Drug Administration has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for the initiation of early Alzheimer's disease treatment. This move allows patients to transition away from traditional intravenous infusions, marking a significant shift toward at-home care options for those managing the condition.
























